IBER

NYSE

Ibere Pharmaceuticals

SectorFinanceIndustryBlank ChecksIPO2021

News25/Ratings0

Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.

Latest news

25 items

1137dSEC
SEC Form 15-12G filed by Ibere Pharmaceuticals
15-12G - IBERE PHARMACEUTICALS (0001835205) (Filer)
1148dSEC
SEC Form 25-NSE filed by Ibere Pharmaceuticals
25-NSE - IBERE PHARMACEUTICALS (0001835205) (Subject)
1163dSEC
Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - IBERE PHARMACEUTICALS (0001835205) (Filer)
1163dNEWS
Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
1164d13D/G
SEC Form SC 13G filed by Ibere Pharmaceuticals
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
1164d13D/G
SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
SC 13G/A - IBERE PHARMACEUTICALS (0001835205) (Subject)
1170d13D/G
SEC Form SC 13G filed by Ibere Pharmaceuticals
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
1170d13D/G
SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
SC 13G/A - IBERE PHARMACEUTICALS (0001835205) (Subject)
1176d13D/G
SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
SC 13G/A - IBERE PHARMACEUTICALS (0001835205) (Subject)
1256dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1350dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1438dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1484dSEC
SEC Form 10-K filed by Ibere Pharmaceuticals
10-K - IBERE PHARMACEUTICALS (0001835205) (Filer)
1529d13D/G
SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
SC 13G/A - IBERE PHARMACEUTICALS (0001835205) (Subject)
1535d13D/G
SEC Form SC 13G filed by Ibere Pharmaceuticals
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
1560d13D/G
SEC Form SC 13G filed by Ibere Pharmaceuticals
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
1623dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1669d13D/G
SEC Form SC 13G filed by Ibere Pharmaceuticals
SC 13G - IBERE PHARMACEUTICALS (0001835205) (Subject)
1711dSEC
SEC Form 10-Q/A filed by Ibere Pharmaceuticals (Amendment)
10-Q/A - IBERE PHARMACEUTICALS (0001835205) (Filer)
1711dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1711dSEC
SEC Form 8-K/A filed by Ibere Pharmaceuticals (Amendment)
8-K/A - IBERE PHARMACEUTICALS (0001835205) (Filer)
1714dSEC
Ibere Pharmaceuticals filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8-K - IBERE PHARMACEUTICALS (0001835205) (Filer)
1723dSEC
Ibere Pharmaceuticals filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
8-K - IBERE PHARMACEUTICALS (0001835205) (Filer)
1742dSEC
SEC Form 10-Q filed by Ibere Pharmaceuticals
10-Q - IBERE PHARMACEUTICALS (0001835205) (Filer)
1791dPR
Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report
PHILADELPHIA, May 28, 2021 /PRNewswire/ -- Ibere Pharmaceuticals (NYSE:IBER) (the "Company") today announced that it received a notice on May 25, 2021 from the New York Stock Exchange (the "NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Quarterly Report") with the Securities and Exchange Commission (the "SEC"). The notice has no immediate effect on the listing of the Company's stock on the NYSE. As disclosed in the Company's Form 12b-25 filed with the SEC on May 18, 2021, on April 12, 2021 the Staff of the SEC re